Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Acute low back pain is one of the most common reasons for all physician visits(1). Phospholipase A2 (PLA2), a potent inflammatory mediator, has demonstrated to be released by discs following injury(4). Clinical practice and animal research suggest that lumbar radicular pain is the result of inflammation of the nerve root in the epidural space(5). The study will evaluate the efficacy of intravenous Dexamethasone for acute disc herniation-induced sciatica. 40 patients aged 18 years or older, who will be transferred to the emergency room due to sciatic pain will be blindly randomized to receive Dexamethasone 30 mg IV for 3 days an tapering off, 10 mg daily, or normal saline. 20 patients will be in each group. The patients will continue their standard care during the study period. Follow up will last for 3 months. Mann-Whitney test will be used for parametric correlation, Wilcoxon for numeral and x² for categorial variables. Dexamethasone IV can help physicians in treating patients with acute sciatic pain.
| Condition | Intervention |
|---|---|
|
RADICULAR PAIN |
Drug: DEXAMETHASONE Other: PLACEBO |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Efficacy of Intravenous Dexamethasone for Acute Disc Herniation-Induced Sciatica |
| Estimated Enrollment: | 40 |
| Study Start Date: | August 2007 |
| Estimated Study Completion Date: | July 2008 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1 TREATMENT GROUP
20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
|
Drug: DEXAMETHASONE |
|
Placebo Comparator: 2
20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
|
Other: PLACEBO |
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients aged 18 years or older presented with acute radicular pain for less than 6 weeks.
Exclusion Criteria:
- Patient with acute infection,
- Psychiatric disorder,
- Uncontroled diabetes,
- Uncontrolede hypertension,
- Severe congestive heart failure,
- Cauda equina syndrome,
- Moderate or severe motor deficit,
- Primary spinal stenosis,
- Pregnancy.
Contacts and Locations| Contact: RADI SHAHIEN, MD | 972 4 6828928 | shahien.r@ziv.health.gov.il |
| Israel | |
| Neurology Unit - Ziv Mc | Recruiting |
| Safed, Israel, 13100 | |
| Contact: RADI SHAHIEN, MD 972 4 6828928 shahien.r@ziv.health.gov.il | |
| Principal Investigator: RADI SHAHIEN, MD | |
| Principal Investigator: | RADI SHAHIEN, MD | ZIV MEDICAL CENTER |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00516009 History of Changes |
| Other Study ID Numbers: | HP-7-247S |
| Study First Received: | August 13, 2007 |
| Last Updated: | August 13, 2007 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Ziv Hospital:
|
RADICULAR PAIN DISC HERNIATION DEXAMETHASONE VAS |
Additional relevant MeSH terms:
|
Hernia Sciatica Pathological Conditions, Anatomical Neuralgia Pain Neurologic Manifestations Nervous System Diseases Sciatic Neuropathy Mononeuropathies Peripheral Nervous System Diseases Neuromuscular Diseases Signs and Symptoms Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate |
BB 1101 Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents |
ClinicalTrials.gov processed this record on June 17, 2013